retatrutide for autoimmune disease Triple hormone receptor agonist metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial GLP-1 Drugs: Ozempic, Mounjaro, Zepbound:

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial

Dysregulation of cytokine production, increased vulnerability to viral infections, autoimmune disorders, malnutrition, and inflammatory reactions are all linked to leptin deficiency/resistance [15]

Pfizer CEO Hints at 3 Weight-Loss Drugs During a Semafor event interview on June 24, 2024, Pfizer CEO Alfred Bourla noted that Pfizer is currently working on three weight-loss treatments

Obesity-related glomerulopathy: an emerging epidemic

Injectable administration eliminates these variables, making it easier to achieve and maintain therapeutic effect

Recent deep mutational scanning of the human IR ectodomain highlights the diversity of pathogenic mechanisms underlying insulin resistance and underscores the need for mutation-informed therapeutic strategies( 13 )